The COVID-19 pandemic has turned RNA into a household word, but what new innovations and changes will we see in the RNA therapeutics space going forward and how many will actually reach the clinic?
Agreement grants Eterna rights to license up to four next-generation iPS cell derived NK and T cell cancer therapies.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for funding RNA-based cell therapies as a panel member at the RNA Cell Therapies Summit.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will participate in an industry leader fireside chat focused on “Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies and Determining Future Outlook and Developments” at the 2nd iPSC-Derived Cell Therapies Summit.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Strategies to Develop Safe Cell Therapies Without Compromising Efficacy” at the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit.